Grifols, S.A. (NASDAQ:GRFS) Shares Sold by State Street Corp

State Street Corp decreased its position in Grifols, S.A. (NASDAQ:GRFS) by 12.2% in the 3rd quarter, HoldingsChannel reports. The firm owned 700,791 shares of the biotechnology company’s stock after selling 96,973 shares during the period. State Street Corp’s holdings in Grifols were worth $6,223,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. GAMMA Investing LLC lifted its stake in shares of Grifols by 49.4% during the third quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 1,135 shares during the period. Signaturefd LLC raised its holdings in Grifols by 66.2% in the 3rd quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 2,153 shares during the last quarter. AQR Capital Management LLC acquired a new stake in shares of Grifols during the second quarter worth $89,000. HighTower Advisors LLC grew its position in shares of Grifols by 12.5% in the third quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company’s stock valued at $123,000 after purchasing an additional 1,546 shares during the period. Finally, Chesapeake Capital Corp IL purchased a new stake in shares of Grifols in the third quarter valued at $148,000.

Grifols Trading Down 2.5 %

GRFS stock opened at $7.65 on Friday. The company has a market cap of $5.26 billion, a price-to-earnings ratio of 7.89 and a beta of 0.43. Grifols, S.A. has a 52 week low of $5.30 and a 52 week high of $12.15. The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11. The business has a fifty day simple moving average of $8.27 and a 200-day simple moving average of $8.12.

Analyst Ratings Changes

Separately, Berenberg Bank raised Grifols to a “strong-buy” rating in a research note on Tuesday, October 29th.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.